
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is well positioned for success in the near-term with upcoming catalysts such as ESMO and TL1A readouts. The company also has a strong pipeline and potential for significant BD activity, providing opportunities for further growth. Merck has a diverse range of products in several therapeutic areas and a strong geographic presence in the US, making it a stable and well-established company in the pharmaceutical industry.
Bears say
Merck & Co is a global biopharmaceutical company that operates through two primary business segments, including research-based biopharmaceutical products and global contract manufacturing and animal health. Factors that could negatively impact the company's stock include slower than anticipated growth for new products, disappointing pipeline data results, successful challenges to key patents, delays in approval of investigational assets, and unfavorable macroeconomic conditions that lead to a market rotation away from defensive stocks. Furthermore, climate change and ESG concerns could lead to increased costs and regulatory pressures that may impact the company's business and reputation.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares